Pharmgate and Cambridge Technologies announced Sept. 8 an agreement between the companies that provides a platform from which the parties can provide commercial, autogenous and prescription vaccine solutions to veterinarians and producers in the U.S. and around the world.

Pharmgate chief executive officer and president Colin Gray said, "This is an exciting agreement embodying the commitment of both companies to providing services and solutions to the global marketplace. Our research and development teams will collaborate and work together under this agreement in designing future and wide-ranging disease solutions benefiting sustained and prudent animal husbandry practices. The overarching goal is to remain flexible and nimble, with the power and ability to react to disease challenges in providing quality, safe and effective best-in-class products in a timely and responsive way.”

According to Cambridge CEO Randy Simonson, “This agreement represents an exciting collaboration that will bring breakthrough technology to veterinarians and producers for the management of disease. The ever-changing landscape of animal health creates an opportunity for two forward-thinking companies like ours to come together and raise the bar in the science of vaccinology.”

Pharmgate LLC, a subsidiary of Jinhe Biotechnology, was established in 2008 with a view to becoming a gateway for global animal health biological, pharmaceutical and nutraceutical products servicing the global marketplace. In close cooperation with its parent and partners, Pharmgate utilizes its manufacturing and regulatory expertise by partnering with forward-thinking manufacturers of popular animal health products. Pharmgate adds value to its partners through its U.S.-based capabilities in manufacturing, formulation development, regulatory affairs, marketing and distribution. This expertise provides manufacturers and partners with direct access to these important animal health markets.

Pharmgate’s mission is to partner with other manufacturers in order to streamline the flow of high-quality, regulations-compliant and affordable animal health products to the end user: the animal feed producer and farmer.

Cambridge Technologies is a precision diagnostics and autogenous vaccine company founded recently in Worthington, Minn. The experienced team at Cambridge provides a full-service diagnostic laboratory, including next-generation sequencing and quality autogenous vaccine manufacturing.